Titan Pharmaceuticals, Inc. (NASDAQOTCBB:TTNP)

CAPS Rating: 1 out of 5

A biopharmaceutical company developing proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone disease and other disorders.

Recs

0
Player Avatar pisspoorpicks (< 20) Submitted: 2/2/2013 11:04:56 PM : Outperform Start Price: $2.10 TTNP Score: -102.30

06/30/2013 Phase 2 trial of elagolix in the treatment of uterine fibroids is expected to be completed in 1H 2013.

06/30/2013 Data from Phase 2b trial of NBI-98854 in tardive dyskinesia patients due 2Q 2013 (Kinect 1 Study).

06/30/2013 Data from second Phase 2b trial of NBI-98854 in tardive dyskinesia patients due mid 2013 (Kinect 2 Study).

Member Avatar pisspoorpicks (< 20) Submitted: 2/13/2013 2:04:00 AM
Recs: 0

Disregard above. Copy & paste error.

04/30/2013 PDUFA for Probuphine, under priority review for Opioid dependence.

Featured Broker Partners


Advertisement